| **Contacts:** | **Wyeth:** Media                  Contacts:Sal                  FotiWyeth                  Pharmaceuticals(484)                  865-3490 Gwen                  FisherWyeth                  Pharmaceuticals(484)                  865-5160 Investor                  Contact:Justin                  VictoriaWyeth(973)                  660-5340 | **Progenics                  Pharmaceuticals, Inc.:** Investor                  Contact:Richard                  W. Krawiec, Ph.D.Vice                  PresidentCorporate                  Affairs(914)                  789-2814rkrawiec@progenics.com Media                  Contact:Aline                  SchimmelWeissComm                  Partners(212)                  301-7218 |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**WYETH        AND PROGENICS TO INITIATE PHASE 2 TRIALS OF ORAL METHYLNALTREXONE IN        CHRONIC-PAIN SETTING**

**Collegeville,        Pa and Tarrytown, NY, October 15, 2007**

*www.clinicaltrials.gov*

----

**About        the Collaboration between Wyeth and Progenics**

**About        Opioid-Induced Constipation**

**About        Methylnaltrexone and the Methylnaltrexone Clinical Program**

**About        the Companies**

**Wyeth        Pharmaceuticals**

----

*WYETH        DISCLOSURE NOTICE: The statements in this press release that are not historical        facts are forward-looking statements based on current expectations of future        events and are subject to risks and uncertainties that could cause actual        results to differ materially from those expressed or implied by such statements.        These risks and uncertainties include the inherent uncertainty of the timing        and        success of, and expense associated with, research, development, regulatory        approval and commercialization of our products, including with respect to        our        pipeline products; government cost-containment initiatives; restrictions        on        third-party payments for our products; substantial competition in our industry,        including from branded and generic products; data generated on our products;        the        importance of strong performance from our principal products and our anticipated        new product introductions; the highly regulated nature of our business; product        liability, intellectual property and other litigation risks and environmental        liabilities; uncertainty regarding our intellectual property rights and those        of        others; difficulties associated with, and regulatory compliance with respect        to,        manufacturing of our products; risks associated with our strategic        relationships; economic conditions including interest and currency exchange        rate        fluctuations; changes in generally accepted accounting principles; trade        buying        patterns; the impact of legislation and regulatory compliance; risks and        uncertainties associated with global operations and sales; and other risks        and        uncertainties, including those detailed from time to time in our periodic        reports filed with the Securities and Exchange Commission, including our        current        reports on Form 8-K, quarterly reports on Form 10-Q and annual report on        Form        10-K, particularly the discussion under the caption "Item 1A, Risk Factors."        The        forward-looking statements in this press release are qualified by these risk        factors. We assume no obligation to publicly update any forward-looking        statements, whether as a result of new information, future developments or        otherwise.*

**Progenics        Pharmaceuticals,        Inc**
*in vivo*

----

*PROGENICS        DISCLOSURE NOTICE: The information contained in this document is current        as of        October 15, 2007. This press release contains forward-looking statements.        Any        statements contained herein that are not statements of historical fact may        be        forward-looking statements. When the Company uses the words "anticipates,"        "plans," "expects" and similar expressions, it is identifying forward-looking        statements. Such forward-looking statements involve risks and uncertainties        which may cause the Company's actual results, performance or achievements        to be        materially different from those expressed or implied by forward-looking        statements. Such factors include, among others, the uncertainties associated        with product development, the risk that clinical trials will not commence        or        proceed as planned, the risks and uncertainties associated with dependence        upon        the actions of our corporate, academic and other collaborators and of government        regulatory agencies, the risk that our licenses to intellectual property        may be        terminated because of our failure to have satisfied performance milestones,        the        risk that products that appear promising in early clinical trials do not        demonstrate efficacy in larger-scale clinical trials, the risk that we may        not        be able to manufacture commercial quantities of our products, the uncertainty        of        future profitability and other factors set forth more fully in the Company's        Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and        other reports filed with the Securities and Exchange Commission, to which        investors are referred for further information. In particular, the Company        cannot assure you that any of its programs will result in a commercial product.        Progenics does not have a policy of updating or revising forward-looking        statements and assumes no obligation to update any forward-looking statements        contained in this document as a result of new information or future events        or        developments. Thus, it should not be assumed that the Company's silence over        time means that actual events are bearing out as expressed or implied in        such        forward-looking statements.*